NPTX2 Recombinant Rabbit mAb (S-4048-54)

NPTX2 (Neuronal Pentraxin 2), also known as NARP (Neuronal Activity-Regulated Protein), is a member of the neuronal pentraxin family, a class of secreted glycoproteins homologous to C-reactive protein. It is primarily expressed in excitatory neurons and plays a critical regulatory role in synaptic plasticity and excitatory synapse formation. Its classic function involves being released into the synaptic cleft during active periods, where it binds to and clusters AMPA-type glutamate receptors on the postsynaptic membrane, thereby enhancing excitatory drive to parvalbumin-positive interneurons (PV-INs) to reinforce circuit inhibition and balance neural network activity. During resting periods, a portion of NPTX2 complexes is cleaved by proteases and released from synapses—this dynamic "synaptic scaling" mechanism is essential for memory updating and refinement of neural circuits. Given this core function, aberrant expression and dysfunction of NPTX2 are closely associated with various neurological disorders: in Parkinson's disease (PD), its expression is upregulated and participates in the pathological process of Lewy bodies; whereas in Alzheimer's disease (AD) and mild cognitive impairment (MCI), its levels are significantly reduced in cerebrospinal fluid and are directly correlated with cognitive decline and synaptic loss, thus making it a reliable biomarker reflecting synaptic dysfunction and disease progression. Furthermore, NPTX2 function is not restricted to the nervous system—it is also expressed in various peripheral tissues including pancreas, heart, and skeletal muscle. In oncology, it exhibits high tissue specificity and complexity: it acts as a pro-oncogenic factor in tumors such as glioma, neuroblastoma, and colorectal cancer, where it promotes tumor growth and metastasis through activating the Wnt/β-catenin signaling pathway in colorectal cancer; conversely, it functions as a tumor suppressor in cancers such as pancreatic cancer and thymic carcinoma, where promoter hypermethylation-induced silencing is associated with poor prognosis in thymic carcinoma patients. This duality makes it a highly challenging but promising potential diagnostic biomarker or therapeutic target.